Palvella Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: George M. Jenkins

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: George M. Jenkins”): 9,907,220 for, 268,834 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 2,899,920 for, 113,110 withheld.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: John Doux, M.D.

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: John Doux, M.D.”): 9,958,528 for, 217,526 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 2,901,140 for, 111,890 withheld.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: Election of three director nominees to serve as Class III directors whose term will expire in 2029: Todd C. Davis

Palvella Therapeutics, Inc.’s own tally for this item (“Elect Director: Todd C. Davis”): 8,321,303 for, 1,854,751 withheld, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 1,826,990 for, 1,186,036 withheld, 4 abstained.

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

Description as filed by funds: APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING TO THE EXTENT THERE ARE INSUFFICIENT VOTES AT THE ANNUAL MEETING TO APPROVE PROPOSAL 5.

Palvella Therapeutics, Inc.’s own tally for this item (“6. Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5”): 7,649,243 for, 2,519,068 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 1,571,298 for, 1,434,082 against, 6,070 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

Description as filed by funds: APPROVAL OF AN AMENDMENT TO THE 2024 EQUITY INCENTIVE PLAN TO INCREASE THE AUTHORIZED SHARES ISSUABLE UNDER THE 2024 PLAN BY 750,000 SHARES.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 59 managers: 1,706,735 for, 1,298,644 against, 6,070 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 3 managers: 800,908 for, 153 against.

Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Palvella Therapeutics, Inc.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers in 2025”): 10,008,180 for, 160,717 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers in 2025, as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 60 managers: 2,956,351 for, 50,608 against, 6,070 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 149 managers: 7,694,222 for, 111,015 against, 68 abstained, 1,385 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: APPROVAL, ON AN ADVISORY BASIS, OF THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 59 managers: 15,008 for, 6,070 abstained, 2,990,133 1 year, 218 3 year, 21 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 144 managers: 1,684,983 for, 35 against, 6,081,128 1 year, 39,288 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE 2026 FISCAL YEAR.

Palvella Therapeutics, Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accountant”): 11,557,687 for, 13,216 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst &Young LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified, as follows:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 3,005,368 for, 12 against, 6,070 abstained.

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.